98 related articles for article (PubMed ID: 8832017)
1. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.
Toren A; Ackerstein A; Gazit D; Or R; Raveh D; Kupolovicz U; Engelhard D; Nagler A
Bone Marrow Transplant; 1996 Jul; 18(1):209-10. PubMed ID: 8832017
[TBL] [Abstract][Full Text] [Related]
2. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT.
Klapholz L; Ackerstein A; Goldenhersh MA; Vardy D; Nagler A
Bone Marrow Transplant; 1993 Jun; 11(6):443-6. PubMed ID: 8334424
[TBL] [Abstract][Full Text] [Related]
3. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT).
Toren A; Or R; Ackerstein A; Nagler A
Bone Marrow Transplant; 1997 Jul; 20(1):67-9. PubMed ID: 9232260
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
[TBL] [Abstract][Full Text] [Related]
5. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
[No Abstract] [Full Text] [Related]
6. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Re D; Bamborschke S; Feiden W; Schröder R; Lehrke R; Diehl V; Tesch H
Bone Marrow Transplant; 1999 Feb; 23(3):295-8. PubMed ID: 10084263
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer.
Meehan KR; Arun B; Gehan EA; Berberian B; Sulica V; Areman EM; Mazumder A; Lippman ME
Bone Marrow Transplant; 1999 Apr; 23(7):667-73. PubMed ID: 10218842
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
[TBL] [Abstract][Full Text] [Related]
10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous hypersensitivity to co-trimoxazole after autologus bone marrow transplantation and immunotherapy with interferon alpha-2A and interleukin-2.
Mehta J; Nagler A; Ackerstein A; Kapelushnik J; Or R
J Assoc Physicians India; 1993 Apr; 41(4):235-6. PubMed ID: 8270579
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
15. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT).
Nagler A; Nagler R; Ackerstein A; Levi S; Marmary Y
Bone Marrow Transplant; 1997 Oct; 20(7):575-80. PubMed ID: 9337059
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
17. [Tuberculous ulcer of the tongue: clinical case].
Ladron de Guevara R
Odontol Chil; 1989 Dec; 37(2):277-9. PubMed ID: 2641965
[TBL] [Abstract][Full Text] [Related]
18. Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse.
Vivancos P; Grañena A; Sarrá J; Grañena A
Bone Marrow Transplant; 1999 Jan; 23(2):169-72. PubMed ID: 10197803
[TBL] [Abstract][Full Text] [Related]
19. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
20. Pseudomembraneous clostridium after autologous bone marrow transplantation.
Kavan P; Sochor M; Nyc O; Lochmann O; Koutecky J; Skala PJ; McClain LK
Bone Marrow Transplant; 1998 Mar; 21(5):521-3. PubMed ID: 9535046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
